

SULPHASALAZINE SHARED CARE PROTOCOL

This Shared Care Protocol is for patients initiated on Sulphasalazine under the Rheumatology Department. The consultant will have detailed the expected treatment regimen in the clinic letter. The first 3 months of prescribing and monitoring will be undertaken by the Rheumatology department. Updates of dosages and results will be completed by the specialist nurses and documented in the patient hand held record as well as sent to the GP practice for information.

As part of the Shared Care LES, it is expected that ALL patients will have a transfer of care at 3 months, unless there are exceptional circumstances (such as unstable results). We would be grateful if your practice would take over the responsibility for:

- Prescribing the Sulphasalazine
- Performing the blood tests and monitoring the results (payment via LES)

If patients fail to attend for their monitoring, we would recommend contacting them to arrange one further monitoring appointment but thereafter to stop prescribing their treatment until the monitoring requirements have been met.

The patient carries a hand held monitoring book, which has been kept up to date by the Rheumatology department, and/or GP prescriber, and contains patient information.

Important Information:

- Repeat prescriptions should be retained separately (i.e. highlighted as different to all other repeat prescriptions), so the GP prescriber can ensure monitoring has been undertaken prior to signing and issuing to patient
- Sulphasalazine is safe in pregnancy and when breastfeeding but may cause reversible oligospermia in men.
- If used in pregnancy, daily Folic acid is advised.
- Sulphasalazine may cause nausea or diarrhea in which case changing to four times daily dosing may help
- Side effects include: Headaches, dizziness, skin rash (if mild, it may respond to topical hydrocortisone and slow reintroduction to previous dose).
- Increased risk of side effects in ANA positive patients
- Sulphasalazine will cause yellow staining of body fluids eg tears, semen, urine (caution with contact lenses)
- Live vaccines should not be given
- Annual flu jab is advised recommended (to be given by GP practice)
- Avoid exposure to chickenpox and shingles. If infection develops it should be treated aggressively with antiviral medication and Rheumatology dept. can be contacted for advice

Treatment is usually started at a dose of 500mg enteric coated once or twice daily after food. This is increased by 500mg each week, if tolerated, up to a dose of 1.0 or 1.5grams twice daily (optimum around 40mg/kg/day). Nausea, indigestion and headache are the most common problems. Dividing the doses into a four times daily regime may help.

Monitoring schedule:

- FBC/ U&E / LFT / CRP every 2 weeks until on stable dose for 6 weeks, then monthly for 3 months
- Then every 3 months up to 12 months
- Then 6 monthly thereafter
- Results to be entered into hand held monitoring booklet

IF	WCC	<3.5x 10 ⁹ /l
	Neutrophils	<1.8x 10 ⁹ /l
	Platelets	<150x 10 ⁹ /l
	ASTorALT	> 100

OR: Severe sore throat / Oral Ulceration / Fever / Rash

Stop medication and contact local Rheumatology service.

If unsure or progressive abnormal trend in blood test results, despite within normal range, please contact by telephone/fax

If CRP elevated (>25) and patient symptomatic, inform Rheumatology department. If CRP suddenly elevated without significant change to joint symptoms assess patient for infection. Occasionally patients run a persistently high CRP without joint symptoms – this will usually be flagged up in clinic letters

Department Contact details:

Fax: 01709 424276
Telephone Helpline: 01709 424739

Consultants:
Dr Gillian Smith 01709 424275 / 424156
Dr Fiona Fawthrop 01709 424275 / 424156
Dr Rakesh Kumari 01709 424275 / 424156

Nurse Specialists:
Sister Sue Elsey + Sister Louise Hale – Bleep 079 via Switch

Specialist Registrar: available on bleep 101 via Switchboard

SULPHASALAZINE SHARED CARE PROTOCOL

Version:	3 (three)
Ratified by:	ROTHERHAM MEDICINES OPTIMISATION GROUP (RMOG)
Date ratified:	1 st November 2017
Title of originator/author:	Dr Rakesh Kumari, Dr Gillian Smith, Dr Fiona Fawthrop, Rheumatology RFT; Eloise Summerfield, Medicines Management Team RCCG
Title of responsible committee/individual:	Consultants Rheumatology RFT; Medicines Management Team RCCG (BNF 10 Prescribing Advisor)
Date issued:	November 2017
Review date:	November 2020
Target audience:	TRFT consultants & nurses Rotherham CCG GPs & nurses

Version	Date	Author	Status	Comment
Version 1	July 2012	Dr James Maxwell RFT Eloise Summerfield RCCG	Archived	First version onto a two page format
Version 2	July 2014	Dr Gillian Smith, Dr Fiona Fawthrop, RFT; Eloise Summerfield, RCCG	Archived	Review – minimal changes
Version 3	Nov 2017	Dr Rakesh Kumari, Dr Gillian Smith, Dr Fiona Fawthrop, RFT; Eloise Summerfield, RCCG	Current version	Extra blood tests at start & dose change. First paragraph re-worded to reflect current practice. Acceptance letter removed as this is now implied under the Shared Care LES